Scientific leader
Dr. Sophie Caillat-Zucman
The success of clinical trials using T cells carrying a chimeric receptor (CAR-T) has demonstrated the fantastic potential of this strategy in malignant hemopathies. However, the CAR-T must be produced individually on demand for each patient, which poses logistical difficulties and has a prohibitive cost for wider use. Our goal is to produce so-called “universal” cells, ready to use for any patient, using Mucosal-associated invariant T (MAIT) cells. We produced CD19-CAR MAIT as proof of concept, and demonstrated their ability to eliminate CD19+ leukemia target cells in vitro. Our research program aims to confirm the anti-tumor efficacy of CD19‐CAR MAIT in vivo and to verify their absence of toxicity in a pre-clinical model (immunodeficient NSG mice), before considering a clinical trial.
Post-doctorant
Laboratory
Hôpital St-Louis, Bâtiment Hayem
1 avenue Claude Vellefaux
75 010 Paris
